Comparative Pharmacology
Head-to-head clinical analysis: MVASI versus SUSVIMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MVASI versus SUSVIMO.
MVASI vs SUSVIMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Ranibizumab is a humanized monoclonal antibody fragment that binds to and inhibits the activity of vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability.
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
10 mg administered via intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
Terminal elimination half-life is approximately 4.9 days (range 3.5–6.7 days) in patients receiving intravitreal injections every 4 weeks. The long half-life supports sustained intravitreal VEGF suppression with monthly dosing.
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Primarily metabolized in the liver via catabolism to small peptides and amino acids; renal elimination of metabolites is negligible as intact drug is not excreted renally. Biliary/fecal excretion is not a significant route. <1% of dose excreted unchanged in urine.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor